Login to Your Account



Novacea Soars On Potential $440M Schering-Plough Deal

By Jennifer Boggs


Thursday, May 31, 2007
Novacea Inc. found a partner for its late-stage prostate cancer drug, Asentar, licensing product rights to Schering-Plough Corp. in exchange for $60 million up front and the potential for $380 million in milestones down the road. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription